2. Signaling Pathways
  3. GPCR/G Protein
  4. RGS Protein
  5. RGS19 Isoform

RGS19

RGS19 (also known as GAIP, Gα-interacting protein) is a member of the regulator of G-protein signaling (RGS) family that functions as a GTPase-activating protein (GAP) for heterotrimeric G-protein α subunits, thereby accelerating GTP hydrolysis and terminating GPCR-mediated signaling pathways[1][2]. Mechanistically, RGS19 preferentially interacts with Gαi family proteins, particularly Gαi3, and suppresses downstream Gαi- and Gαq-linked signal transduction, establishing a key regulatory checkpoint in cellular responses to extracellular stimuli[3][4]. Consistent with its role in signal attenuation, RGS19 has been localized to membrane-associated compartments and clathrin-coated vesicles, supporting spatial regulation of G-protein signaling and receptor trafficking processes[5]. In disease-relevant settings, phosphorylation-dependent activation of RGS19 has been reported to enhance its GAP activity and regulate autophagy-related signaling in human colon cancer cells, indicating a functional connection between GPCR regulation and tumor-associated cellular adaptation pathways[6]. Compared with related RGS isoforms such as RGS4, which also exhibits GAP activity toward Gαi proteins, RGS19 is distinguished by its strong association with Gαi3 and its characteristic membrane-targeting mechanisms mediated by lipid modification and protein-protein interactions[2][3][7]. For experimental applications, RGS19 is widely used as a model RGS protein for investigating GPCR desensitization, G-protein deactivation kinetics, and molecular mechanisms governing selective RGS-Gα interactions[1][2][7].

RGS19 Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-13509
    CCG-50014
    		Inhibitor 99.62%
    CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.
  • HY-U00431
    CCG 203769
    		Inhibitor 99.76%
    CCG 203769 is a selective G protein signaling (RGS4) inhibitor, which blocks the RGS4-Gαo protein-protein interaction in vitro with an IC50 of 17 nM.